(Q33641367)

28 July 2017

title

Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study (English)

1 reference

28 July 2017

5

Ludwig Kappos

1 reference

28 July 2017

4

Michael Hutchinson

1 reference

28 July 2017

1

Ralf Gold

1 reference

28 July 2017

3

Amit Bar-Or

1 reference

28 July 2017

16

David H Miller

1 reference

28 July 2017

Douglas L Arnold

2

1 reference

28 July 2017

Eva Havrdova

6

1 reference

28 July 2017

David G MacManus

7

1 reference

28 July 2017

Tarek A Yousry

8

1 reference

28 July 2017

Carlo Pozzilli

9

1 reference

28 July 2017

Krysztof Selmaj

10

1 reference

28 July 2017

Marianne T Sweetser

11

1 reference

28 July 2017

Ray Zhang

12

1 reference

28 July 2017

Minhua Yang

13

1 reference

28 July 2017

James Potts

14

1 reference

28 July 2017

Mark Novas

15

1 reference

28 July 2017

Nuwan C Kurukulasuriya

17

1 reference

28 July 2017

Robert J Fox

18

1 reference

28 July 2017

Theodore J Phillips

19

1 reference

28 July 2017

publication date

19 May 2016

1 reference

Multiple Sclerosis Journal

28 July 2017

published in

1 reference

28 July 2017

volume

23

1 reference

28 July 2017

issue

2

1 reference

28 July 2017

page(s)

253-265

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

28 July 2017

copyright license

start time

11 July 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: Patient management considerations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5418934

The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5418934

Gastrointestinal Tolerability of Delayed-Release Dimethyl Fumarate in a Multicenter, Open-Label Study of Patients with Relapsing Forms of Multiple Sclerosis (MANAGE)

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5418934

Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5418934

Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5418934

A systematic review of the incidence and prevalence of cancer in multiple sclerosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5418934

Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5418934

Reliability of classifying multiple sclerosis disease activity using magnetic resonance imaging in a multiple sclerosis clinic

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5418934

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5418934

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5418934

Placebo-controlled trial of oral laquinimod for multiple sclerosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5418934

Clinical applications of imaging disease burden in multiple sclerosis: MRI and advanced imaging techniques

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5418934

Novel MRI approaches to assess patients with multiple sclerosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5418934

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5418934

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5418934

Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5418934

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5418934

Developing therapeutics for the treatment of multiple sclerosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5418934

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5418934

Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5418934

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5418934

Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: Experiences of an international panel

21 June 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516649037

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516649037

The relationship between whole brain volume and disability in multiple sclerosis: a comparison of normalized gray vs. white matter with misclassification correction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516649037

Randomized trial of oral teriflunomide for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516649037

Association of Neocortical Volume Changes With Cognitive Deterioration in Relapsing-Remitting Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516649037

PML in a patient with lymphocytopenia treated with dimethyl fumarate

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27207449

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1177/1352458516649037

1 reference

28 July 2017

1 reference

28 July 2017

1 reference